137 related articles for article (PubMed ID: 22387577)
1. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial.
Samama MM; Contant G; Spiro TE; Perzborn E; Flem LL; Guinet C; Gourmelin Y; Martinoli JL;
Clin Appl Thromb Hemost; 2012; 18(2):150-8. PubMed ID: 22387577
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.
Samama MM; Contant G; Spiro TE; Perzborn E; Guinet C; Gourmelin Y; Le Flem L; Rohde G; Martinoli JL;
Thromb Haemost; 2012 Feb; 107(2):379-87. PubMed ID: 22187012
[TBL] [Abstract][Full Text] [Related]
3. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
[TBL] [Abstract][Full Text] [Related]
4. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin.
Mani H; Rohde G; Stratmann G; Hesse C; Herth N; Schwers S; Perzborn E; Lindhoff-Last E
Thromb Haemost; 2012 Jul; 108(1):191-8. PubMed ID: 22534775
[TBL] [Abstract][Full Text] [Related]
5. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban.
Harenberg J; Marx S; Krämer R; Giese C; Weiss C
Blood Coagul Fibrinolysis; 2011 Dec; 22(8):637-41. PubMed ID: 21986465
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories.
Asmis LM; Alberio L; Angelillo-Scherrer A; Korte W; Mendez A; Reber G; Seifert B; Stricker H; Tsakiris DA; Wuillemin WA
Thromb Res; 2012 Apr; 129(4):492-8. PubMed ID: 21840043
[TBL] [Abstract][Full Text] [Related]
7. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
Barrett YC; Wang Z; Frost C; Shenker A
Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
[TBL] [Abstract][Full Text] [Related]
8. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
[TBL] [Abstract][Full Text] [Related]
9. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.
Gouin-Thibault I; Flaujac C; Delavenne X; Quenet S; Horellou MH; Laporte S; Siguret V; Lecompte T
Thromb Haemost; 2014 Feb; 111(2):240-8. PubMed ID: 24172843
[TBL] [Abstract][Full Text] [Related]
10. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban.
Douxfils J; Tamigniau A; Chatelain B; Chatelain C; Wallemacq P; Dogné JM; Mullier F
Thromb Haemost; 2013 Oct; 110(4):723-31. PubMed ID: 23846172
[TBL] [Abstract][Full Text] [Related]
11. Assays for measuring rivaroxaban: their suitability and limitations.
Lindhoff-Last E; Samama MM; Ortel TL; Weitz JI; Spiro TE
Ther Drug Monit; 2010 Dec; 32(6):673-9. PubMed ID: 20844464
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.
Gosselin RC; Adcock D; Hawes EM; Francart SJ; Grant RP; Moll S
Thromb Haemost; 2015 Jan; 113(1):77-84. PubMed ID: 25413383
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of routine coagulation assays to direct oral anticoagulants: patient samples versus commercial drug-specific calibrators.
Lim MS; Chapman K; Swanepoel P; Enjeti AK
Pathology; 2016 Dec; 48(7):712-719. PubMed ID: 27780603
[TBL] [Abstract][Full Text] [Related]
14. Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation.
Molenaar PJ; Dinkelaar J; Leyte A
Clin Chem Lab Med; 2012 Oct; 50(10):1799-807. PubMed ID: 23089710
[TBL] [Abstract][Full Text] [Related]
15. Correlating prothrombin time with plasma rivaroxaban level.
Rodgers R; Bagot CN; Lawrence C; Hickman G; McGurk M; Tait RC
Br J Haematol; 2013 Dec; 163(5):685-7. PubMed ID: 24219334
[No Abstract] [Full Text] [Related]
16. Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma.
Conversy B; Blais MC; Dunn M; Gara-Boivin C; Carioto L; del Castillo JR
Vet J; 2013 Nov; 198(2):437-43. PubMed ID: 24053991
[TBL] [Abstract][Full Text] [Related]
17. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban.
Harenberg J; Marx S; Weiss C; Krämer R; Samama M; Schulman S;
J Thromb Haemost; 2012 Jul; 10(7):1433-6. PubMed ID: 22947062
[No Abstract] [Full Text] [Related]
18. Determination of rivaroxaban in human plasma samples.
Harenberg J; Erdle S; Marx S; Krämer R
Semin Thromb Hemost; 2012 Mar; 38(2):178-84. PubMed ID: 22422332
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.
Douxfils J; Mullier F; Loosen C; Chatelain C; Chatelain B; Dogné JM
Thromb Res; 2012 Dec; 130(6):956-66. PubMed ID: 23006523
[TBL] [Abstract][Full Text] [Related]
20. Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban.
Gosselin RC; Adcock Funk DM; Taylor JM; Francart SJ; Hawes EM; Friedman KD; Moll S
Arch Pathol Lab Med; 2014 Dec; 138(12):1680-4. PubMed ID: 25427046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]